Search Results

Introduction Endocrine therapy (ET) is often used as first-line treatment in patients with hormone receptor-positive (HR+) breast cancer and preferred to chemotherapy when there are no signs of visceral crisis ( Reinert & Barrios 2015 ). In

published studies assessing hormonal influences on meningiomas, in order to highlight potential prognostic and therapeutic values of endocrine therapy. Data for this review were identified by searches of Medline and Cancerlit. The search terms ‘meningioma

endocrine therapy. The AR structure is similar to that of other steroid receptors; it consists of well-conserved DNA-and ligand-binding domains and the N-terminal region that contains a variable number of polyglutamine and polyglycine repeats. A more

ovariectomy, was the first endocrine therapeutic modality described for breast cancer ( Beatson 1896 ), the selective estrogen receptor modulator (SERM) tamoxifen has been the mainstay endocrine therapy of breast cancer for the last 25 years. Tamoxifen is

estrogen receptor (ER) is used to direct treatment of disease with endocrine therapies that target the critical dependence of such breast cancers on estrogenic signaling ( Jordan et al . 1987 , Musgrove & Sutherland 2009 , Hammond et al . 2010 , Harris

Introduction Oestrogen receptor α-positive (ER+) breast cancer constitutes more than 70% of all breast cancers ( Cardoso et al. 2012 ). Both early and metastatic disease are treated effectively with endocrine therapies, which downregulate

( Yamashita & Iwase 2002 ). In the present study, we examined the expression of Stat3 and Stat5 in 517 human breast cancer tissues and analyzed the significance for prognosis and prediction of response to endocrine therapy. Our results indicated that positive

-points may also be improved. Conclusions With the increasing numbers of childhood brain tumour survivors reaching adulthood awareness of endocrine late effects of cancer therapy is essential. These patients should be followed

% of invasive breast cancers. Importantly, ER is the primary target for both chemoprevention and endocrine therapy of breast cancer ( Ali & Coombes 2002 ). The ER status of breast tumours (determined as a binary factor of − or +) provides prognostic